Tyra Biosciences, Inc. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 62/100
What the filing says
Tyra Biosciences established an at-the-market (ATM) equity offering of up to $250,000,000 of common stock through TD Securities (USA) LLC as sales agent, pursuant to a Form S-3 registration statement filed May 8, 2025 and amended August 4, 2026. Separately, the company amended its Non-Employee Director Compensation Program effective May 28, 2026, establishing annual board retainers ranging from $5,000 to $40,000 plus committee fees, with initial equity grants of stock options to purchase 26,300 shares and annual grants of 13,160 shares.
Why this rating
ATM represents 84% of market cap ($250M/$297M), providing substantial capital flexibility. Director compensation reflects governance maturation. Material but dilutive financing tool; execution and pricing unknown.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.